Drugs / HPV E6-specific TCR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03578406 | Sep 2018 → Apr 2022 | cervical cancer, head and neck squamous cell carcinoma | Xinqiao Hospital of Chongqing | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV E6-specific TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03578406 ↗ |
| Modality | Cell therapy | “Engineered T cells bearing a TCR (TCR-T) that can specifically recognize the presented HPV antigen” NCT03578406 ↗ |
| Route | Intravenous | “Patients were infused with HPV E6-specific TCR-T cells” NCT03578406 ↗ |